Edition:
United Kingdom

Aspen Pharmacare Holdings Ltd (APNJ.J)

APNJ.J on Johannesburg Stock Exchange

9,928.00ZAc
7:39am GMT
Change (% chg)

190.00 (+1.95%)
Prev Close
9,738.00
Open
9,740.00
Day's High
9,962.00
Day's Low
9,740.00
Volume
70,491
Avg. Vol
1,698,164
52-wk High
29,800.00
52-wk Low
6,899.00

Latest Key Developments (Source: Significant Developments)

Aspen Pharmacare Says FY Normalised Headline Earnings From Cont Ops To Be In Line With H1 Pct Decline
Thursday, 7 Mar 2019 

March 7 (Reuters) - Aspen Pharmacare Holdings Ltd ::UNAUDITED INTERIM FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2018.EMBARKED ON A STRATEGIC REVIEW OF ITS EUROPEAN AND SOUTH AFRICAN COMMERCIAL PHARMACEUTICALS BUSINESSES.HY NHEPS 743 CENTS VERSUS 814 CENTS.HY REVENUE FROM CONTINUING. OPERATIONS 19.67 BILLION RAND VERSUS 19.51 BILLION RAND.DECIDED TO SPLIT S.AFRIC COMMERCIAL PHARMACEUTICALS INTO 2 DIVISIONS TO ACHIEVE HEIGHTENED PRODUCT AND CUSTOMER FOCUS.NORMALISED HEADLINE EARNINGS FROM CONTINUING OPERATIONS (AT CER) FOR FULL YEAR EXPECTED TO BE IN LINE WITH PERCENTAGE DECLINE RECORDED IN H1.CONVERSION RATE OF OPERATING PROFITS TO CASH OF BETWEEN 90% AND 100% IS ANTICIPATED FOR FULL FINANCIAL YEAR.CONCLUDED AGREEMENTS RELATING TO DIVESTMENT AND DISCONTINUATION OF NON-CORE PHARMACEUTICAL PORTFOLIO IN ASIA PACIFIC REGION.DIVIDEND OF 315 CENTS PER SHARE HAS BEEN PAID DURING HY (2017: 287 CENTS).  Full Article

Aspen Says Roy Andersen To Retire From Board
Thursday, 7 Mar 2019 

March 7 (Reuters) - Aspen Pharmacare Holdings Ltd ::JSE: APN - CHANGES TO THE BOARD AND ITS COMMITTEES.ASPEN PHARMACARE HOLDINGS LTD - APPOINTMENT OF THEMBA MKHWANAZI AND BEN KRUGER AS INDEPENDENT NON-EXECUTIVE DIRECTORS AND RETIREMENT OF ROY ANDERSEN.ASPEN PHARMACARE - ROY ANDERSEN HAS CONFIRMED THAT HE WILL, DUE TO TENURE CONSIDERATIONS, RETIRE FROM BOARD WITH EFFECT FROM 30 SEPTEMBER 2019.  Full Article

Aspen Pharmacare Holdings Reached Deal With Funders During Period To Nov
Friday, 14 Dec 2018 

Dec 14 (Reuters) - Aspen Pharmacare Holdings Ltd ::ASPEN PHARMACARE HOLDINGS - CLARIFY THAT AGREEMENT WAS REACHED WITH ASPEN'S SYNDICATE OF FUNDERS DURING PERIOD TO NOV.ASPEN PHARMACARE HOLDINGS - DEAL PROVIDING MULTI-CURRENCY FACILITIES TO NEGOTIATE TEMPORARY ADJUSTMENT TO LEVERAGE RATIO COVENANT AS AT 31 DEC.  Full Article

Aspen On Track To Meet FY Guidance Of Commercial Pharma Organic Revenue Growth
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Aspen Pharmacare Holdings Ltd ::ASPEN PHARMACARE HOLDINGS LTD - ON TRACK TO MEET ITS FULL YEAR GUIDANCE OF COMMERCIAL PHARMA ORGANIC REVENUE GROWTH.ASPEN - FY GUIDANCE OF COMMERCIAL PHARMA ORGANIC REVENUE GROWTH RANGING BETWEEN 1% AND 4% BASED ON PERFORMANCE FOR FIVE MONTHS TO 30 NOVEMBER 2018.ASPEN - MANUFACTURING REVENUE FROM APIS HAS DONE BETTER THAN EXPECTED FOR FIVE MONTHS TO 30 NOVEMBER AND IS IN LINE WITH REVENUE FOR COMPARABLE PERIOD.ASPEN PHARMACARE - POSITIVE PERFORMANCE FROM COMMERCIAL PHARMA IN MOST EMERGING MARKETS, JAPAN OFFSET BY WEAKER PERFORMANCE IN EUROPE & RUSSIA IN FY.ASPEN PHARMACARE- SIGNIFICANT PROGRESS MADE IN PROCURING FULFILMENT OF CONDITIONS PRECEDENT TO DISPOSAL TO B.A.S. S.A. OF ASPEN'S NUTRITIONALS BUSINESS.  Full Article

Aspen Pharmacare Sells Global Nutritionals Business For EUR 739.8 Mln
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Aspen Pharmacare Holdings Ltd ::DIVESTMENT OF GLOBAL NUTRITIONALS BUSINESS TO LACTALIS FOR EUR739,8 MILLION.CONCLUDED AN AGREEMENT TO DIVEST OF ITS NUTRITIONALS BUSINESS TO LACTALIS GROUP.FY ASPEN IMPROVED REVENUE BY 3% TO R42,6 BILLION.FY NORMALISED HEADLINE EARNINGS PER SHARE BY 10% TO 1 605 CENTS.DEAL PROCEEDS OF EUR739,8 MILLION TO BE REDUCED BY EUR62 MILLION, WILL BE UTILISED TO BUY-OUT ASPEN'S JV PARTNERS IN NEW ZEALAND, CHINA.ANTICIPATED THAT DEAL WILL BE COMPLETED WITHIN SIX MONTHS OF SEPT. 13 ANNOUNCEMENT.STRONG OPERATING CASH FLOWS ARE ANTICIPATED TO CONTINUE.HAS DECLARED A GROSS DIVIDEND, WHICH IS PAID FROM INCOME RESERVES, OF 315 CENTS PER ORDINARY SHARE TO SHAREHOLDERS.  Full Article

Aspen Pharmacare Says Harding Loevner Holds 5.01 Pct in Co
Thursday, 12 Jul 2018 

July 12 (Reuters) - Aspen Pharmacare Holdings Ltd ::HARDING LOEVNER LP NOTIFIED CO THAT THEY ACQUIRED INTEREST IN CO'S SECURITIES, NOW AMOUNTING TO 5.01 PCT OF COMPANY, EFFECTIVE 5 JULY.  Full Article

Aspen's Infant Formula Unit Is Said To Draw Reckitt, Perrigo - Bloomberg
Wednesday, 16 May 2018 

May 16 (Reuters) - :ASPEN'S INFANT FORMULA UNIT IS SAID TO DRAW RECKITT, PERRIGO - BLOOMBERG, CITING SOURCES.FRENCH DAIRY GROUP LACTALIS AND AUSTRALIA'S INOVA PHARMACEUTICALS ARE ALSO WEIGHING OFFERS FOR A STAKE IN ASPEN'S INFANT FORMULA UNIT - BLOOMBERG.  Full Article

Aspen Says To Review Global Nutritionals Business
Monday, 29 Jan 2018 

Jan 29 (Reuters) - Aspen Pharmacare Holdings Ltd ::STRATEGIC REVIEW OF ASPEN’S GLOBAL NUTRITIONALS BUSINESS.‍HAS BEEN EXPLORING OPTIONS TO ENHANCE VALUE OF ITS GLOBAL NUTRITIONALS BUSINESS ("NUTRITIONALS") SINCE RECEIVING AN UNSOLICITED APPROACH IN Q3 OF LAST YEAR​.‍CFDA OF REGISTRATION OF ASPEN'S INFANT MILK FORMULA BRAND, ALULA, ASPEN HAS DECIDED TO FORMALISE ITS REVIEW OF STRATEGIC OPTIONS FOR NUTRITIONALS​.‍RANGE OF OPTIONS WILL BE CONSIDERED INCLUDING, INTER ALIA, INTRODUCTION OF A STRATEGIC PARTNER THAT COULD UNLOCK APPROPRIATE VALUE​.‍APPOINTED CENTERVIEW PARTNERS UK LLP AS FINANCIAL ADVISOR TO ASSIST IN STRATEGIC REVIEW PROCESS​.  Full Article

Aspen Pharmacare Receives Approval For Registration Of Alula In China​
Monday, 15 Jan 2018 

Jan 15 (Reuters) - Aspen Pharmacare Holdings Ltd ::‍ASPEN RECEIVES APPROVAL FOR REGISTRATION OF ALULA IN CHINA​.  Full Article

Aspen Pharmacare Says Has Had No Contact With Viceroy Research
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Aspen Pharmacare Holdings Ltd ::HAS HAD NO CONTACT WITH VICEROY RESEARCH AND, AS SUCH, IS UNABLE TO CONFIRM THAT SPECULATION IS CORRECT.IS NOT AWARE OF ANY INFORMATION OF A PRICE SENSITIVE NATURE THAT REQUIRES COMMUNICATION TO SHAREHOLDERS​.  Full Article

UPDATE 1-South Africa's rand firms on improved risk appetite, Naspers lift stocks

JOHANNESBURG, March 11 South Africa's rand firmed on Monday, helped by increasing demand for emerging market currencies amid a slew of disappointing economic data in developed markets and growth warnings from central banks.